tbuckley/cabot-search huggingface dataset:
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Authors: Muriel Elhai, Marouane Boubaya, Oliver Distler, Vanessa Smith, Marco Matucci-Cerinic, Juan José Alegre Sancho, Marie-Elise Truchetet, Yolanda Braun-Moscovici, Florenzo Iannone, Pavel I Novikov, Alain Lescoat, Elise Siegert, Ivan Castellví, Paolo Airó, Serena Vettori, Ellen De Langhe, Eric Hachulla, Anne Erler, Lidia Ananieva, Martin Krusche, F J López-Longo, Jörg H W Distler, Nicolas Hunzelmann, Anna-Maria Hoffmann-Vold, Valeria Riccieri, Vivien M Hsu, Maria R Pozzi, Codrina Ancuta, Edoardo Rosato, Carina Mihai, Masataka Kuwana, Lesley Ann Saketkoo, Carlo Chizzolini, Roger Hesselstrand, Susanne Ullman, Sule Yavuz, Simona Rednic, Cristian Caimmi, Coralie Bloch-Queyrat, Yannick Allanore
Journal: Annals of the Rheumatic Diseases (2019)

Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice. Methods We performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab. Results 254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47–5.32]; p=0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)&gt;10% (OR: 1.03 [0.55–1.94]; p=0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56–3.53], p&lt;0.0001). Patients treated concomitantly with mycophenolate mofetil had a trend for better outcomes as compared with patients receiving rituximab alone (delta FVC: 5.22 [0.83–9.62]; p=0.019 as compared with controls vs 3 [0.66–5.35]; p=0.012). Conclusion Rituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
Somatic copy number amplification and activating somatic mutations of EZH2 Y641 drive melanoma by epigenetic remodeling.
Authors: Peter Hersey, Jessamy Tiffen, Stuart Gallagher, Fabian Filipp
Journal: Journal of Clinical Oncology (2015)

e22072 Background: The polycomb repressive complex (PRC) is instrumental for chromatin remodeling and recruitment of proteins for epigenetic modifications. The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is associated with methylation-dependent gene repression. Prior studies have shown that EZH2 has activating mutations in approximately 3% of melanoma and that progression of melanoma is associated with increased expression of EZH2. Methods: A systems biology approach was applied to the skin cutaneous melanoma (SKCM) dataset of the Cancer Genome Atlas (TCGA) to connect somatic mutation and copy number alterations of EZH2 to epigenetic and transcriptional control. We describe the genomic landscape of PRC2-associated genes based on exome, genome, transcriptome, and methylome sequencing data from 460 TCGA malignant melanoma patients and related this to DNA methylation status and patient survival. Results: We found recurring somatic gain-of-function driver mutations in the active site of the SET domain of EZH2 at Y641 in 5.04% of patients as well as somatic copy number amplification of EZH2 in 5.4%. Somatic mutations were mutually exclusive between EZH2 and the methyltransferases DNMT3A or DNMT3B. CpG markers in patients with gain-of-function mutations of EZH2 were hyper-methylated causing gene-silencing at the transcriptional level. Patients with EZH2 overexpression or activating mutations had significantly lower median survivals than other patients. Conclusions: Somatic gain-of-function driver mutations in the active site of the SET domain of EZH2 at Y641 are central to oncogenic PRC2 action. These structural alterations provide PRC2 with enhanced activity in melanoma. Somatic mutations in a mutually exclusive setting between EZH2 and DNMT3A or DNMT3B emphasize the role of de novo DNA methylation by PRC2. In vitro somatically amplified or activated EZH2 leads to increased H3K27me3, a histone mark connected with gene silencing. EZH2 presents itself as an epigenetic cancer driver by modulating chromatin remodelers and silencing tumor suppressors and is a possible treatment target in melanoma.
Abstract P052: Subgingival Dysbiosis Predicts Longitudinal Glucose Change
Authors: Ryan T Demmer, Pauline Trinh, Michael Rosenbaum, Charles LeDuc, Rudolph Leibel, Paolo C Colombo, Bruce Paster, Panos N Papapanou, Moïse Desvarieux, David R Jacobs
Journal: Circulation (2017)

Background: Microbial dysbiosis and translocation of microbial products across digestive tract mucosal surfaces are hypothesized risk factors for impaired glucose regulation. We specifically investigated whether measures of subgingival dysbiosis predicted longitudinal fasting plasma glucose (FPG) change. Methods: The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS) enrolled 300 diabetes-free adults (77% female) aged 20-55 years (mean±SD=34±10). Subgingival plaque samples were collected and analyzed using 16S rDNA sequencing (Illumina MiSeq; NexGEN) using the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) protocol. FPG was measured at baseline and after two-years. Microbial community alpha-diversity was calculated using Simpson’s index. Multivariable linear regressions modeled 2-year glucose change on baseline relative abundance of 376 individual oral taxa (in separate models) with adjustment for age, sex, race/ethnicity, education, smoking status, BMI and baseline glucose levels. All taxa with a p-value&lt;0.05 were used to construct a microbial dysbiosis-index (MD-index) defined as the ratio of taxa abundance in organisms positively vs. inversely associated with FPG change. The MD-index was subsequently used in regression models to predict glucose change. Statistical significance was based on a false discovery rate (FDR)&lt;0.05 or a Bonferroni corrected p-value (1x10 -4 ). Results: Mean 2-year FPG change±SD was 1.5±8 mg/dl. Mean±SD values of MD-index were 2.2±2.4. Baseline levels of 23 taxa were associated with FPG change (p&lt;0.05), 11 of which had inverse associations. Among these 23 taxa, Treponema HOT238, Leptotrichia HOT498 and Stomatobaculum HOT097 had an FDR&lt;0.05. The MD-index was inversely correlated with alpha-diversity (r=-0.19, p&lt;0.01). Mean FPG-change±SE in the 3 rd vs. 1 st tertile of MD-index were 4.5±0.9 vs. -1.6±0.9 (p&lt;1x10 -4 ). Conclusion: Increased levels of microbial dysbiosis, reflecting decreased microbial diversity, were associated with increased 2-year glucose change among young, diabetes-free subjects.
Treatment Strategies for Deficiency of Adenosine Deaminase 2
Authors: Amanda K. Ombrello, Jing Qin, Patrycja M. Hoffmann, Parag Kumar, Deborah Stone, Anne Jones, Tina Romeo, Beverly Barham, Gineth Pinto-Patarroyo, Camilo Toro, Ariane Soldatos, Qing Zhou, Natalie Deuitch, Ivona Aksentijevich, Sherry L. Sheldon, Susan Kelly, Ada Man, Karyl Barron, Michael Hershfield, Willy A. Flegel, Daniel L. Kastner
Journal: New England Journal of Medicine (2019)

Adenosine Deaminase 2 Deficiency and TNF Inhibition The manifestations of a deficiency of adenosine deaminase 2, a genetic disease, include early-onset lacunar stroke. In a series of 15 patients wi...
Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Authors: Robert W. Chen, Joycelynne M. Palmer, Alex Francisco Herrera, Saro H. Armenian, Matthew Mei, Leslie Popplewell**, Abbey Fueger, Imran Qasim, Tracy Stiller, Steven T. Rosen, Stephen J. Forman, Larry W Kwak
Journal: Blood (2017)
Impact of <i>FCGR3A</i> V158F and <i>FCGR2A</i> H131R variants on ofatumumab efficacy in DLBCL and CLL.
Authors: Sarah M. Glass, Pamela St Jean, Kay Murphy, Louise Clapham, Eddie Carden, Astrid McKeown, Michele Gorczyca, Oliver Wright, Michael Fennessy, Ira V. Gupta, Colin F. Spraggs
Journal: Journal of Clinical Oncology (2015)

e22085 Background: Ofatumumab is an anti-CD20 monoclonal antibody that induces cell lysis primarily through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). Given ADCC is regulated by Fc-gamma receptors (FCGRs), two nonsynonymous variants were evaluated in 5 clinical studies for an association with ofatumumab efficacy. Methods: Germline DNA was collected for ofatumumab-treated subjects with DLBCL from OMB110927 and OMB110928 (81% (227/281)), and with CLL from OMB110911, OMB115991 and OMB114242 (89% (353/397)). FCGR3A V158F and FCGR2A H131R genotypes generated by validated TaqMan and Sanger sequencing assays were evaluated for association with improved ofatumumab efficacy. One-tailed tests were performed under an additive genetic model by exact logistic regression for overall response (OR) and a Cox proportional hazards model for progression-free survival (PFS). The significance threshold for the primary objective assessing FCGR3A 158V on OR was p < 0.05 in CLL and DLBCL. The threshold for remaining objectives was p < 0.02 in CLL and p < 0.01 in DLBCL. Results: In the primary DLBCL meta-analysis using the OMB110927 investigator-assessed and OMB110928 independent review committee OR evaluations, a non-significant improvement in OR to ofatumumab (n = 225; p = 0.059, odds ratio = 0.69 (95% CI 0.44, 1.10)) as well as a non-significant improvement in PFS (p > 0.01 hazards ratio = 0.82 (95% CI 0.62, 1.09)) was seen with FCGR3A V allele carriage. A post-hoc meta-analysis of the investigator-assessed efficacy endpoints in both DLBCL studies yielded a statistically significant improvement in OR (n = 225; p = 0.029, odds ratio = 0.62 (95% CI 0.38, 1.01)). There was no evidence of an effect of this variant on ofatumumab efficacy in CLL (p > 0.05). Also, there was no evidence of an effect of FCGR2A H131R on ofatumumab response in CLL (p > 0.02) or DLBCL (p > 0.01). Conclusions: A trend for improvement in response to ofatumumab with FCGR3A 158V allele carriage was observed in DLBCL. These results suggest a role of ADCC in ofatumumab treatment of DLBCL subjects, and subject to independent confirmation, that this variant may have value as a candidate marker for improved efficacy in that setting.
A Direct Podocalyxin–Dynamin-2 Interaction Regulates Cytoskeletal Dynamics to Promote Migration and Metastasis in Pancreatic Cancer Cells
Authors: Bin Sheng Wong, Daniel J. Shea, Panagiotis Mistriotis, Soontorn Tuntithavornwat, Robert A. Law, Jake M. Bieber, Lei Zheng, Konstantinos Konstantopoulos
Journal: Cancer Research (2019)

Abstract The sialoglycoprotein podocalyxin is absent in normal pancreas but is overexpressed in pancreatic cancer and is associated with poor clinical outcome. Here, we investigate the role of podocalyxin in migration and metastasis of pancreatic adenocarcinomas using SW1990 and Pa03c as cell models. Although ezrin is regarded as a cytoplasmic binding partner of podocalyxin that regulates actin polymerization via Rac1 or RhoA, we did not detect podocalyxin–ezrin association in pancreatic cancer cells. Moreover, depletion of podocalyxin did not alter actin dynamics or modulate Rac1 and RhoA activities in pancreatic cancer cells. Using mass spectrometry, bioinformatics analysis, coimmunoprecipitation, and pull-down assays, we discovered a novel, direct binding interaction between the cytoplasmic tail of podocalyxin and the large GTPase dynamin-2 at its GTPase, middle, and pleckstrin homology domains. This podocalyxin–dynamin-2 interaction regulated microtubule growth rate, which in turn modulated focal adhesion dynamics and ultimately promoted efficient pancreatic cancer cell migration via microtubule- and Src-dependent pathways. Depletion of podocalyxin in a hemispleen mouse model of pancreatic cancer diminished liver metastasis without altering primary tumor size. Collectively, these findings reveal a novel mechanism by which podocalyxin facilitates pancreatic cancer cell migration and metastasis. Significance: These findings reveal that a novel interaction between podocalyxin and dynamin-2 promotes migration and metastasis of pancreatic cancer cells by regulating microtubule and focal adhesion dynamics.
SAT-020-Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites
Authors: Theresa Bucsics, Maria Schoder, Mattias Mandorfer, Philipp Schwabl, Nicolas Göschl, Sophie Hoffmann, Johanna Grünberger, Franz Karnel, Josef Karner, Markus Peck-Radosavljevic, Thomas Reiberger
Journal: Journal of Hepatology (2019)
The Society of Vascular Surgery Practice Guidelines on the Care of Patients With Abdominal Aortic Aneurysms
Authors: Michol A. Cooper, Gilbert R. Upchurch
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Multifaceted Program to Reduce Job Strain in ICU Nurses
Authors: François-Xavier Lesage, Guillaume Choron, Frederic Dutheil
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT-273-Impact of age on routinely available non-invasive tests for the discrimination of advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib
Authors: Naim Alkhouri, Zobair M. Younossi, Eric Lawitz, Vincent Wai-Sun Wong, Manuel Romero Gomez, Takeshi Okanoue, Michael Trauner, Guang Chen, Lulu Wang, Kathryn Kersey, Georgia Li, Robert Myers, Stephen Djedjos, Stephen Harrison, Zachary Goodman, Quentin Anstee
Journal: Journal of Hepatology (2019)
A prospective analysis of the impact of support group participation in women with gynecological cancer.
Authors: Andrea Garrick, Adam Pyrzak, Bunja Jane Rungruang, Jeff Campbell, Ramses F. Sadek, Sharad A. Ghamande
Journal: Journal of Clinical Oncology (2015)

e20604 Background: Unlike breast cancer support group literature, there is no data in women with gynecologic cancers who have different perspectives about their disease and therapy. We have a well-established (10 years old) active grass root level support group unique to women with gynecologic cancers that meets monthly. Our goal was to investigate perceived benefits of support group participation. Methods: We developed a prospective questionnaire to evaluate the CSRA Gynecologic Oncology Support Group (CGOSG) participant’s perceived effects of attending the group on their side effects and disease status. The questionnaire was then distributed to patients attending CGOSG meetings over a 4 month period. 47 surveys were collected for analysis; Wilcox rank sum test was used as appropriate. Results: The common cancers were 52% ovarian and 26% endometrial, and 62% were currently on treatment. The 3 top reasons that patients attended CGOSG were 28% physician drive, 26% to meet other women with the same diagnosis and 22% to learn more about their cancer. The top 3 expectations of patients were 28% emotional support, 21% bonding/companionship and 14% cancer education. The top 3 concerning physical side effects from their cancer or therapy were 21% fatigue, 14% memory loss, and 14% peripheral neuropathy. Patients with more than 5 visits reported that CGOSG participation improved their most concerning physical side effect (fatigue) with a median score of 7.5 ± 4 out of 10. The top 3 concerning emotional side effects identified were 26% fear of recurrence, 20% living with uncertainty, and 15% defining a new sense of normal. Patients reported the CGOSG improved their most concerning emotional side effect (fear of recurrence) with a median score of 9 ± 2 out of 10. Patients with more than one visit who are not currently on therapy reported a higher quality of life score (p = 0.001) and perceived a positive impact on their cancer (p = 0.02) compared to patients on cancer. Conclusions: This is the first attempt to understand the impact of well-organized support group attendance on women with gynecological cancers. These results indicate that these women struggle with fear of recurrence and uncertainty, but are able to find some solace.
FRI-439-Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation
Authors: Bogdan Procopet, Gilberto Silva-Junior, Elba Llop, Tellez luis, Anna Darnell, Ángeles García-Criado, Fanny Turon, Anna Baiges, Marta Magaz, José Luis Calleja Panero, Agustin Albillos, Juan Carlos Reverter, Jaume Bosch, Virginia Hernandez-Gea, garcia pagan juan carlos
Journal: Journal of Hepatology (2019)
THU-497-Molecular fingerprint of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
Authors: Sara Torrecilla, Roser Pinyol, Huan Wang, Carla Montironi, Carmen Andreu-Oller, Wei Qiang Leow, Agrin Moeini, Claudia Oliveira, Venancio Avancini Ferreira Alves, Anja Lachenmayer, Stephanie Roessler, Beatriz Minguez, Peter Schirmacher, Paolo Boffetta, Jean-François Dufour, Swan N Thung, Andrew Uzilov, Flair Jose Carrilho, Charissa Chang, Daniela Sia, Josep M. Llovet
Journal: Journal of Hepatology (2019)
Sudden Gains in Cognitive Behavioural Therapy and Focal Psychodynamic Therapy for Anorexia Nervosa: Findings from the ANTOP Study
Authors: Timo Brockmeyer, Silke Michalek, Stephan Zipfel, Beate Wild, Gaby Resmark, Martin Teufel, Katrin Giel, Martina de Zwaan, Andreas Dinkel, Stephan Herpertz, Markus Burgmer, Bernd Löwe, Sefik Tagay, Eva Rothermund, Almut Zeeck, Wolfgang Herzog, Hans-Christoph Friederich
Journal: Psychotherapy and Psychosomatics (2019)
The Equivalence Thesis: Why Timers Do Not Successfully Resuscitate the Acts/Omissions and Withdrawal/Withholding Debate
Authors: Dominic Wilkinson, Ella Butcherine, Julian Savulescu
Journal: The American Journal of Bioethics (2019)

In mid February 1400, King Richard II is said to have died of starvation in a castle in northern England. He had been deposed, but the people of England were reluctant to execute the king. Instead ...
PS-049-Tenofovir alafenamide for hepatitis B virus prophylaxis post-liver transplantation is associated with improved renal function: An interim analysis of a multicenter real-world experience
Authors: Ryan Perumpail, Saro Khemichian, Krutika Lakhoo, Alexander Do, Gina Choi, Francisco Durazo, Mohamed El-Kabany, Sammy Saab, Ronald Busuttil, Steven-Huy Han
Journal: Journal of Hepatology (2019)
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
Authors: T. Jiang, C. Zhou
Journal: Annals of Oncology (2019)

Background: Brain metastasis (BM) is the intractable disease in patients (Pts) with advanced non-small-cell lung cancer (NSCLC). Previous studies reported that EGFR-TKI plus bevacizumab (Ebe) could result in a significant prolongation of progression-free survival (PFS) than EGFR-TKI (E) alone. This study aimed to investigate whether Ebe could provide survival benefit than E alone in EGFR-mutant NSCLC Pts with BM. Methods: Pts with EGFR-mutant NSCLC and radiologically confirmed BM (number > 3) were included. Pts with liver or leptomeningeal metastases were excluded. Intracranial PFS (iPFS) was defined as the time from the date of initiation of 1st treatment to the date of intracranial progression or death and was censored at the date of last tumor assessment (when carried out). Systemic PFS (sPFS) was defined as the time from the date of initiation of 1st treatment to the date of systemic progression (except intracranial progression) or death and was censored at the date of last tumor assessment (when carried out). Results: 164 Pts were identified. 121 received E and 43 received Ebe as 1st treatment. Response rate was marginally higher in Ebe group than that in monotherapy group (69.7% vs. 52.9%, p = 0.055). Ebe was associated with a significantly longer iPFS (13.5 vs. 7.3 m, P < 0.001) and sPFS (14.4 vs. 8.8 m, P < 0.001) than E monotherapy. Importantly, median OS was markedly longer in Ebe group than in E group (30.1 vs. 22.4 m, P < 0.001). Different types of EGFR-TKIs showed comparable efficacy when combined with bevacizumab. However, erlotinib was associated with a significantly longer iPFS but similar sPFS and OS when compared with gefitinb and icotinib monotherapy. Multivariate analysis revealed that addition of bevacizumab was independently associated with prolonged iPFS (HR = 0.45, P < 0.001), sPFS (HR = 0.47, P < 0.001) and OS (HR = 0.50, P < 0.001). Conclusions: The current study indicated that Ebe demonstrated the prolonged survival benefit than E alone in EGFR-mutant NSCLC Pts with multiple BM. These findings suggest that this strategy should be further explored in large-scale, strictly designed clinical trials as a standard treatment option in this clinical scenario. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
SAT-009-Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis
Authors: Alberto Amador, Sara Cobo, Ariadna Padulles, Raul Rigo, Inmaculada Grau, Fe Tubau, Albert Garcia-Sumalla, Nuria Padullés Zamora, José Castellote
Journal: Journal of Hepatology (2019)